3M is in a multi-year overhang from PFAS and earplug litigation settlements and faces structural revenue declines after the Solventum spin. Operating leverage has narrowed and the dividend was cut materially. New CEO restructuring is delivering some cost saves but topline growth remains negative in healthcare and consumer.
Signals scoped to US · Company-specific tagging coming soon.